{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:36:31Z","timestamp":1790750191682,"version":"4.1.0"},"reference-count":74,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,7,27]],"date-time":"2004-07-27T00:00:00Z","timestamp":1090886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced\u2010stage follicular lymphoma (FL) and mantle cell lymphoma (MCL) cannot be cured using conventional chemotherapy. Fludarabine, the most widely used purine analog, exhibits a particularly high level of activity against small lymphocytic lymphoma and chronic lymphocytic leukemia (CLL). Numerous studies have investigated the efficacy of fludarabine as a single agent or in combination with other cytostatic compounds in the treatment of FL and MCL. Hematologic toxicity is the most commonly observed adverse event in patients treated with fludarabine, but serious infectious complications are relatively rare. Fludarabine monotherapy has proven to be particularly effective in the treatment of FL; however, complete responses (CRs) are observed in only approximately 20\u201340% of all cases. In contrast, combinations containing fludarabine and anthracyclines or alkylating agents have yielded superior response rates and longer periods of progression\u2010free survival (PFS), and the addition of the anti\u2010CD20 antibody rituximab appears to yield even better results. In a randomized trial, an immunochemotherapy regimen consisting of a fludarabine\u2010containing combination and rituximab resulted in superior remission and survival rates compared with the fludarabine\u2010containing combination alone. In summary, fludarabine has proven to be a safe and effective agent in the treatment of indolent lymphoma. In particular, combinations containing fludarabine, anthracyclines and\/or alkylating agents, and rituximab have yielded remarkable CR and PFS rates. Consequently, current research efforts have focused on the use of fludarabine\u2010containing combinations in the first\u2010line treatment of FL and MCL. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.20483","type":"journal-article","created":{"date-parts":[[2004,7,27]],"date-time":"2004-07-27T19:01:25Z","timestamp":1090954885000},"page":"883-893","source":"Crossref","is-referenced-by-count":29,"title":["The role of fludarabine in the treatment of follicular and mantle cell lymphoma"],"prefix":"10.1002","volume":"101","author":[{"given":"Georg","family":"Lenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,8,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_6_3_2","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"20","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol."},{"key":"e_1_2_6_4_2","first-page":"93","article-title":"Mantle cell lymphomas","volume":"84","author":"Hiddemann W","year":"1999","journal-title":"Haematologica."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059155"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-003-0023-x"},{"key":"e_1_2_6_8_2","first-page":"861","article-title":"Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of the event\u2010free survival in patients with mantle cell lymphoma (MCL)\u2014results of a prospective randomized European intergroup study","volume":"98","author":"Hiddemann W","year":"2001","journal-title":"Blood."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11838"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053541"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.1.19.19"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2640"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241020-00002"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843"},{"key":"e_1_2_6_16_2","first-page":"A10","article-title":"Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross\u2010link removal","volume":"38","author":"Koehl U","year":"1997","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0469"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03014.x"},{"key":"e_1_2_6_20_2","first-page":"3501","article-title":"Fludarabine compared with CVP chemotherapy in newly diagnosed patients with Stages III and IV low grade malignant non\u2010Hodgkin's lymphoma. Final analysis of a prospective randomized Phase III intergroup study in 381 patients","volume":"98","author":"Hagenbeek A","year":"2001","journal-title":"Blood."},{"key":"e_1_2_6_21_2","first-page":"28","article-title":"Fludarabine single\u2010agent therapy for relapsed low\u2010grade non\u2010Hodgkin's lymphomas: a Phase II study of the German Low\u2010Grade Non\u2010Hodgkin's Lymphoma Study Group","volume":"20","author":"Hiddemann W","year":"1993","journal-title":"Semin Oncol."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.514"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.546"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.790"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.773"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2003.07.008"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb00165.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.068"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097721"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008381105849"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200210000-00002"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1069(199809)16:3<107::AID-HON630>3.0.CO;2-7"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.047"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200205000-00009"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01765.x"},{"key":"e_1_2_6_36_2","first-page":"194","article-title":"Predictive factors for infectious complications in patients with lymphoproliferative disorders treated with fludarabine combinations without corticosteroids","volume":"13","author":"Seymour JF","year":"2002","journal-title":"Ann Oncol."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0269"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830490207"},{"key":"e_1_2_6_40_2","first-page":"502","article-title":"Fludarabine\/cytoxan\/mitoxantrone (FLU\/CY\/MITO) as front\u2010line therapy in low\u2010grade NHL (LGL)","volume":"13","author":"Spriano M","year":"2002","journal-title":"Ann Oncol."},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.987"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3611"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1999.01364.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1885"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05300.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.71"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1449"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01379.x"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009057639"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.128"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2454"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00092-8"},{"key":"e_1_2_6_53_2","first-page":"484","article-title":"Combined immuno\u2010chemotherapy (R\u2010FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma\u2014final results of a prospective randomized trial of the GLSG","volume":"4","author":"Dreyling MH","year":"2003","journal-title":"Hematol J."},{"key":"e_1_2_6_54_2","first-page":"344","article-title":"A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first\u2010line treatment in patients with follicular lymphoma (FL)","volume":"100","author":"Zinzani PL","year":"2002","journal-title":"Blood."},{"key":"e_1_2_6_55_2","first-page":"1392","article-title":"High clinical and molecular response rate in elderly patients with advanced stage follicular lymphoma treated at diagnosis with a brief chemo\u2010immunotherapy FND + rituximab","volume":"100","author":"Vitolo U","year":"2002","journal-title":"Blood."},{"key":"e_1_2_6_56_2","first-page":"2246","article-title":"Phase II study with fludarabine and cyclophosphamide puls rituximab (FC+R) in relapsed follicular lymphoma patients","volume":"100","author":"Sacchi S","year":"2002","journal-title":"Blood."},{"key":"e_1_2_6_57_2","first-page":"1393","article-title":"Results of a Phase II study employing a combination of fludarabine, cyclophosphamide and rituximab (FCR) as primary therapy for patients with advanced follicluar lymphoma (FL): the Israel Cooperative Lymphoma Group","volume":"100","author":"Cohen A","year":"2002","journal-title":"Blood."},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_2_6_59_2","first-page":"564","article-title":"Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance","volume":"22","author":"McLaughlin P","year":"2003","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008347425795"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.1997.tb00321.x"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.579"},{"key":"e_1_2_6_63_2","first-page":"530a","article-title":"Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL)","volume":"90","author":"Bosch F","year":"1997","journal-title":"Blood."},{"key":"e_1_2_6_64_2","first-page":"184","article-title":"Fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen as first\u2010line therapy in younger patients with advanced stage follicular lymphoma (FL)","volume":"13","author":"Montoto S","year":"2002","journal-title":"Ann Oncol."},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008228709612"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30152"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_2_6_72_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of rituximab on patients with follicular and mantle\u2010cell lymphoma","volume":"11","author":"Ghielmini M","year":"2000","journal-title":"Ann Oncol."},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982806"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.253"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10240"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20483","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:50:09Z","timestamp":1760262609000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,18]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1002\/cncr.20483"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20483","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,18]]}}}